

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FLATWING PHARMACEUTICALS, LLC and
MYLAN PHARMACEUTICALS INC.,
Petitioners,

v.

ANACOR PHAMACEUTICALS, INC.,
Patent Owner.

Case No. IPR2018-00169¹
U.S. Patent No. 9,566,289

PATENT OWNER'S SURREPLY

¹ Case No. IPR2018-01359 has been joined with this proceeding

TABLE OF CONTENTS

PATENT OWNER’S SURREPLY	5
ARGUMENT	6
I. What Is Actually Not In Dispute	6
II. Petitioners Fail to Rebut Anacor’s Arguments.....	9
A. Petitioners Fail to Rebut Anacor’s Evidence of Teaching Away	9
1. Petitioners Do Not Dispute Dr. Lane’s Analysis that Samour in Combination with the Cited Art and Evidence of Record as a Whole Teaches Away	9
2. The Cited Art Teaches Away from 5% Even Under Petitioners’ Incorrect Legal Standard	10
3. Petitioners’ Pivot to Overlapping Ranges in the Cited Art Does Not Rebut Anacor’s Evidence of Teaching Away	12
B. Petitioners Fail to Rebut Anacor’s Evidence That Formulating Boron-Containing Compounds Was Not Routine	14
III. Petitioners’ Criticisms of Anacor’s Experts Are Irrelevant	16
A. Petitioners Mischaracterize Dr. Lane’s Opinions	17
B. Dr. Reider is Qualified to Opine on Aspects of Transungual Drug Delivery That Require Expertise in Chemistry.....	18
IV. Dr. Kahl’s Rebuttal Opinions Regarding Brehove Are Conclusory and Not Entitled to Any Weight.....	19
V. Dr. Murthy’s Reliance on Anacor’s Post-Priority Dose-Ranging Studies Should be Rejected as Pure Hindsight.....	21
CONCLUSION	24

TABLE OF AUTHORITIES

Cases:

<i>Alcon Research, Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012)	6
<i>Allergan, Inc. v. Sandoz Inc.</i> , 796 F.3d 1293 (Fed. Cir. 2015).....	11
<i>Cardiac Pacemakers, Inc. v. St. Jude Med. Inc.</i> , 381 F.3d 1371 (Fed. Cir. 2004).....	22
<i>Dura Auto. Sys. of Ind., Inc. v. CTS Corp.</i> , 285 F.3d 609 (7th Cir. 2002)	10
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013)	11
<i>Genetics Inst., LLC v. Novartis Vaccines & Diagnostics, Inc.</i> , 655 F.3d 1291 (Fed. Cir. 2011)	13
<i>Honeywell Int’l Inc. v. Mexichem Amanco Holding S.A.</i> , 865 F.3d 1348 (Fed. Cir. 2017).....	22
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Patent Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012).....	22
<i>In re Peterson</i> , 315 F.3d 1325 (Fed. Cir. 2003)	13
<i>Leo Pharm. Prods., Ltd. v. Rea</i> , 726 F.3d 1346 (Fed. Cir. 2013)	7
<i>Millennium Pharms., Inc. v. Sandoz, Inc.</i> 862 F.3d 1356 (Fed. Cir. 2017)	21
<i>PGS Geophysical AS v. Iancu</i> , 891 F.3d 1354 (Fed. Cir. 2018)	10
<i>Santarus, Inc. v. Par Pharm. Inc.</i> , 694 F.3d 1344 (Fed. Cir. 2012).....	16
<i>SkinMedica, Inc. v. Histogen Inc.</i> , 727 F.3d 1187 (Fed. Cir. 2017).....	20

Rules:

Fed. R. Evid. 70310
Fed. R. Evid. 80220

There are two principal reasons why claims 10 and 12–15 of U.S. Patent No. 9,566,289 (“the ’289 patent,” Ex. 1001) are patentable over the art cited by FlatWing and Mylan. *First*, as explained in Anacor’s Patent Owner’s Response, a person of ordinary skill in the art (“POSA”) in 2005 would have used a concentration of tavaborole higher than the 5% w/w recited in claims 10 and 12–15 because the cited art teaches away from 5%. A POSA would have also expected tavaborole to have high keratin-binding affinity, a fact which would have led a POSA to a higher concentration in order to overcome the notoriously difficult challenge of delivering drugs through the human nail plate.

Second, Anacor’s evidence establishes that a POSA in 2005 would not have arrived at the recited concentration through routine experimentation, including “routine” dose-ranging studies, because the reactivity of boron-containing compounds such as a tavaborole would have been expected to render their formulation highly unpredictable—and thus far from routine. Indeed, the record in this case contains only two pre-priority formulations of boron-containing active ingredients—the formulation of a bortezomib prodrug in VELCADE[®] and Brehove’s formulation of the dioxaborinanes of Biobor JF[®]—and a POSA would have known both to suffer from significant stability problems.

Petitioners’ reply fails to rebut Anacor’s arguments and evidence.

Petitioners first erroneously suggest that the previous Board and Federal Circuit

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.